July 18, 2018 10:12 AM EDT
News Briefing

Cel­lec­tar climbs (then sinks) on PhII DL­B­CL da­ta; Vyr­i­ad inks deal with Pfiz­er/Mer­ck KGaA

ENDPOINTS

→ The stock is yo-yoing for Madi­son, WI-based Cel­lec­tar Bio­sciences $CLRB, which climbed yes­ter­day on news of a Phase II can­cer tri­al and im­me­di­ate­ly dropped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times